DRONABINOL
ANTIEMETIC · ANOREXIA FROM HIV ·+1
RHODES PHARMA L
Drug class
Cannabis and Cannabinoid Receptor Agonists
Cannabis and cannabinoid receptor agonists comprise a pharmacological group of natural plant-derived extracts and synthetic compounds that bind to and activate cannabinoid receptors—primarily CB1 and CB2—within the human endocannabinoid system. Read more about Cannabis and Cannabinoid Receptor Agonists
11 drugs in this class 11 manufacturers
Drugs in Cannabis and Cannabinoid Receptor Agonists
DRONABINOL
ANTIEMETIC · ANOREXIA FROM HIV ·+1
CHARTWELL RX LL
Filter & compare in the drug finder →
Opens the drug finder with Cannabis and Cannabinoid Receptor Agonists preselected. Add indication or manufacturer filters there.
Cannabis and cannabinoid receptor agonists comprise a pharmacological group of natural plant-derived extracts and synthetic compounds that bind to and activate cannabinoid receptors—primarily CB1 and CB2—within the human endocannabinoid system.
While the exact phrase functions broadly as an administrative and pharmacological category rather than a single standardized FDA class, agents within this spectrum exert their therapeutic effects by modulating neurotransmitter release and central signaling pathways.
In clinical practice, regulatory-approved cannabinoid agonists such as dronabinol and nabilone are indicated for chemotherapy-induced nausea and vomiting as well as anorexia-related weight loss in patients with HIV/AIDS, while related botanical preparations and investigational formulations target neuropathic pain, multiple sclerosis spasticity, and seizure disorders.
-
nih.gov
Cannabis and cannabinoid receptor agonists comprise a pharmacological group of natural plant-derived extracts and synthetic compounds that bind to and activate cannabinoid receptors—primarily CB1 and CB2—within the human endocannabinoid system
-
legislativeanalysis.org
Cannabis and cannabinoid receptor agonists comprise a pharmacological group of natural plant-derived extracts and synthetic compounds that bind to and activate cannabinoid receptors—primarily CB1 and CB2—within the human endocannabinoid system
-
iowa.gov
Cannabis and cannabinoid receptor agonists comprise a pharmacological group of natural plant-derived extracts and synthetic compounds that bind to and activate cannabinoid receptors—primarily CB1 and CB2—within the human endocannabinoid system While the exact phrase functions broadly as an administrative and pharmacological category rather than a single standardized FDA class, agents within this spectrum exert their therapeutic effects by modulating neurotransmitter release and central signaling...
-
fda.gov
While the exact phrase functions broadly as an administrative and pharmacological category rather than a single standardized FDA class
-
ancan.org
While the exact phrase functions broadly as an administrative and pharmacological category rather than a single standardized FDA class In clinical practice, regulatory-approved cannabinoid agonists such as dronabinol and nabilone are indicated for chemotherapy-induced nausea and vomiting as well as anorexia-related weight loss in patients with HIV/AIDS, while related botanical preparations and investigational formulations target neuropathic pain, multiple sclerosis spasticity, and seizure disord...
-
nih.gov
While the exact phrase functions broadly as an administrative and pharmacological category rather than a single standardized FDA class, agents within this spectrum exert their therapeutic effects by modulating neurotransmitter release and central signaling pathways
-
fda.gov
In clinical practice, regulatory-approved cannabinoid agonists such as dronabinol and nabilone are indicated for chemotherapy-induced nausea and vomiting as well as anorexia-related weight loss in patients with HIV/AIDS, while related botanical preparations and investigational formulations target neuropathic pain, multiple sclerosis spasticity, and seizure disorders
-
nih.gov
In clinical practice, regulatory-approved cannabinoid agonists such as dronabinol and nabilone are indicated for chemotherapy-induced nausea and vomiting as well as anorexia-related weight loss in patients with HIV/AIDS, while related botanical preparations and investigational formulations target neuropathic pain, multiple sclerosis spasticity, and seizure disorders
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.